Generic Drug Manufacturer Hikma Providing Credits for 340B Overcharges

Hikma Pharmaceuticals USA, the U.S. division of U.K.-based generic drug manufacturer Hikma Pharmaceuticals plc, is crediting 340B covered entities for overcharges on a long list of NDCs from the fourth quarter of 2017 through the fourth quarter of 2020.

The

Read More »

Surprise Amendment to Senate Budget Bill Could Portend Busy 340B Legislative Session

Sen. Mike Braun's (R-Ind.) 340B amendment to require more data reporting echoes the thrust of a bill he introduced in the last session of Congress. | Source: C-SPAN

A Republican amendment offered, then tabled, in the U.S. Senate Feb. 4-5 to a budget bill linked to Democrats’ forthcoming COVID-19 relief package could have led to Senate action related to “improving transparency” in the 340B program “through data reporting.”

Read More »

EXCLUSIVE: Bipartisan U.S. House Group Circulating 340B Sign-on Letter to Becerra

The bipartisan group of six U.S. House members that got 217 total representatives last fall—173 Democrats and 44 Republicans—to sign a letter opposing efforts to replace up-front 340B drug discounts with back-end rebates began circulating a new 340B sign-on letter

Read More »

Drug Companies Are Looking at Multiple Ways to Reduce their 340B Exposure

Drug manufacturer tactics to get a handle on 340B sales growth fall into three buckets: Strategic/legal approaches, claims-scrubbing and other operational capabilities, and “demand-side” ways to reduce exposure to 340B discounts. | Source: IQVIA

Some drug manufacturers have grabbed headlines and precipitated lawsuits for ending 340B pricing on drugs dispensed by contract pharmacies. But behind the scenes, drug companies also are investing in other ways to reduce their exposure to 340B program sales, which

Read More »

Democrats Shake Up Lineup on Key Health Committees Impacting 340B

Sen. Elizabeth Warren (D-Mass.) gave up her seat on the HELP Committee for one on the coveted Finance Committee. | Source: C-SPAN

U.S. Senate Democrats late Tuesday afternoon announced their committee assignments for the 117th Congress. Senate Republicans had not yet announced their committee members as of this morning. However, Sen. Richard Burr (N.C.) will be the ranking Republican on the Health,

Read More »

Two New Manufacturer Notices to 340B Entities on HRSA Website

The generic drug manufacturer recently required to repay covered entities for charging above the ceiling price following an audit has posted a notice on the U.S. Health Services and Resources Administration (HRSA) website about recalculation of ceiling prices and “potential

Read More »

Court Freezes Trump’s Rule Banning Pharma Rebates to PBMs

The Biden administration and Pharmaceutical Care Management Association (PCMA), the trade association for pharmaceutical benefit managers (PBMs), have agreed to postpone, from January 1, 2022, to January 1, 2023, the effective date of the Trump administration rule eliminating safe harbor

Read More »

Sanofi Lifts 340B Contract Pharmacy Requirements for Some Providers But Many Are Still Affected

Health centers and four types of hospitals still have to upload their 340B contract pharmacy claims data to a Sanofi vendor to keep getting 340B discounts on Sanofi products. | Source: Shutterstock

Drug manufacturer Sanofi has exempted 11 of the 16 types of health care providers eligible to participate in the 340B program from its conditions on 340B pricing for its products dispensed by contract pharmacies. However, consolidated health center programs (CH),

Read More »

AmeriSourceBergen Has Resumed Distributing 340B-Priced Bausch Health Drugs

340B pricing on Bausch Health products is being restored to AmeriSourceBergen's ordering platforms, 340B Report has learned. | Source: Shutterstock

Drug manufacturer Bausch Health and distributor AmeriSourceBergen Corp. (ABC) apparently have settled their differences and 340B pricing on Bausch Health products is being restored to ABC’s ordering platforms, 340B Report has learned.

Bausch Health blindsided 340B covered entities on

Read More »

Half of Health Care Execs Surveyed Expect Biden to Act on Pharma’s 340B Pricing Denials

Half of health care industry executives surveyed last month think President Biden will take action against drug manufacturers that have stopped offering 340B pricing on their products. | Source: Advis

Half (50 percent) of a sample of health care industry C-suite executives surveyed last month expect the Biden administration to “formally obligate drug manufacturers to offer 340B pricing,” consulting firm Advis reports in its first health care industry leadership survey

Read More »
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
×

*Sign up for news summaries and alerts from 340B Report

Site Footer Live